Akoya Biosciences

Expanding Reagent Offerings And Diagnostics Will Widen Platform Adoption

AnalystConsensusTarget

Not Invested

Based on Analyst Price Targets

Published

05 Apr 25

Updated

01 May 25

Views

n/a

AnalystConsensusTarget's Fair Value

n/a

-42.7%

-5.1%

-42.7%

-5.1%

You can edit this narrative until May 12 6:01 AM. Then, changes will post as Updates.

Author's Valuation

US$2.5850.0% undervalued

AnalystConsensusTarget Fair Value

Narrative

Updates4

Shared on 01 May 25

Fair value Decreased 12%

AnalystConsensusTarget has decreased future PE multiple from 14.1x to 12.7x.

Shared on 24 Apr 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 17 Apr 25

Fair value Decreased 4.58%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 09 Apr 25

Fair value Increased 124%

AnalystConsensusTarget has increased revenue growth from 9.2% to 11.4%, increased future PE multiple from 6.6x to 14.5x and increased shares outstanding growth rate from 0.0% to 0.0%.

AnalystConsensusTarget Fair Value

US$2.58

50.0% undervalued

Future estimation in

Growth p.a.

Decrease

Increase

Current revenue growth rate

7.43%

Life Sciences revenue growth rate

0.26%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

Decrease

Increase

Current discount rate

9.31%

Calculation

US$13.90m

Earnings '28

12.73x

PE Ratio '28

US$176.91m

Market Cap '28

US$176.91m

Market Cap '28

51.13m

No. shares '28

US$3.46

Share Price '28

US$3.46 Share Price '28

Discounted to 2025 @ 9.39% p.a.

US$2.64

Fair Value '25